How to Help Your Patients Find Bismuth Subcitrate/Metronidazole/Tetracycline in Stock: A Provider's Guide

Your Patient Needs Bismuth Subcitrate/Metronidazole/Tetracycline — Here's How to Help Them Get It

You've diagnosed an H. pylori infection and prescribed Bismuth Subcitrate/Metronidazole/Tetracycline (Pylera). It's the right clinical decision — bismuth quadruple therapy is a guideline-recommended first-line treatment with eradication rates of 85-90%. But then your patient calls back: their pharmacy doesn't have it.

This scenario has become increasingly common. While not in a formal FDA shortage, Bismuth Subcitrate/Metronidazole/Tetracycline faces intermittent supply constraints that can delay treatment and frustrate patients. Here's a practical, step-by-step approach to help your patients get the medication they need.

Current Availability Snapshot

As of 2026, the availability picture for Bismuth Subcitrate/Metronidazole/Tetracycline looks like this:

• Two manufacturers: AbbVie (brand-name Pylera) and Par Pharmaceutical (generic, launched March 2023)
• Not in formal FDA shortage but intermittent stockouts continue at the pharmacy level
• Generic is more widely distributed and is the version most pharmacies will stock
• Regional variability: Availability differs by area, pharmacy chain, and wholesaler relationships

Why Patients Can't Find It

Several factors contribute to the difficulty:

• Niche indication: H. pylori treatment is a relatively low-volume prescription category, so pharmacies often don't maintain standing inventory.
• Limited manufacturer base: With only two producers, any supply disruption creates outsized impact.
• Complex formulation: The three-drug combination capsule is harder to manufacture than single-ingredient generics.
• Pharmacy ordering cycles: Many pharmacies only order this medication reactively (when a prescription comes in), adding 1-3 days of delay.
• Cost barriers: At $900+ for the brand and $305-500 for the generic at retail, some patients abandon prescriptions at the pharmacy counter.

What Providers Can Do: 5 Practical Steps

Step 1: Check Availability Before the Patient Leaves

Use Medfinder for Providers to check which pharmacies near your patient currently have Bismuth Subcitrate/Metronidazole/Tetracycline in stock. This takes seconds and can prevent the patient from visiting a pharmacy that can't fill the prescription.

If you know a specific pharmacy has it, send the prescription directly there via e-prescribing.

Step 2: Specify Generic Substitution

When e-prescribing, explicitly allow generic substitution. The generic version is:

• FDA-approved as therapeutically equivalent (same active ingredients, same doses)
• More widely available than brand-name Pylera
• Significantly cheaper ($187-355 with a coupon vs. $900+ for the brand)

Including a note like "generic acceptable" or selecting the generic option in your EHR gives the pharmacy maximum dispensing flexibility.

Step 3: Prepare a Backup Prescription

Have a contingency plan ready. If the combination capsule isn't available within 24-48 hours, consider sending a backup prescription for traditional bismuth quadruple therapy:

• Bismuth Subsalicylate (Pepto-Bismol) 524 mg, 4 times daily
• Metronidazole 250 mg, 4 times daily
• Tetracycline 500 mg, 4 times daily
• Omeprazole 20 mg, twice daily

Duration: 10-14 days. This regimen uses the same drugs and has equivalent efficacy. The main trade-off is a higher pill burden (14+ pills/day vs. 12 capsules/day plus PPI).

Step 4: Educate the Patient on How to Search

Empower patients with specific instructions:

• Share the Medfinder link so they can check pharmacy stock themselves
• Suggest trying independent pharmacies, which often have more flexible wholesaler relationships
• Remind them to ask for the generic by name: "Bismuth Subcitrate Potassium/Metronidazole/Tetracycline Hydrochloride"
• Let them know most pharmacies can special-order the medication within 1-3 business days

Consider sharing our patient guide: How to find Bismuth Subcitrate/Metronidazole/Tetracycline in stock near you.

Step 5: Address Cost Proactively

Cost is a common reason patients don't fill prescriptions. Before the patient leaves, discuss:

• Discount coupons: GoodRx, SingleCare, and RxGo coupons can reduce the generic to as low as $187
• Patient assistance: AbbVie's Allergan Patient Assistance Program provides Pylera free to qualifying uninsured patients (1-800-347-4500 or abbvieaccess.com)
• Traditional quadruple therapy: If cost is the primary barrier, the separate-pill regimen often totals under $50

For a comprehensive patient resource, direct them to our article on saving money on Bismuth Subcitrate/Metronidazole/Tetracycline.

When to Consider Alternatives

If Bismuth Subcitrate/Metronidazole/Tetracycline (in any form) isn't accessible within a clinically appropriate timeframe, consider these guideline-recommended alternatives:

• Concomitant therapy: PPI + Amoxicillin + Clarithromycin + Metronidazole (10-14 days) — widely available, good for areas with <15% dual resistance
• Rifabutin triple therapy (Talicia): Omeprazole + Amoxicillin + Rifabutin — excellent for salvage therapy and areas with high Clarithromycin resistance
• Vonoprazan-based regimens (Voquezna): Newer option with a potent acid suppressor, approved 2023

For a clinical comparison, see our overview of alternatives to Bismuth Subcitrate/Metronidazole/Tetracycline.

Workflow Tips for Your Practice

Consider incorporating these workflow adjustments to minimize disruption when prescribing this medication:

• Create a prescribing template in your EHR that includes both the combination capsule and the separate-pill backup regimen, so you can quickly switch if needed.
• Bookmark Medfinder for Providers on your workstation for quick pharmacy stock checks during patient encounters.
• Train your clinical staff to check availability proactively when H. pylori treatment is anticipated.
• Keep patient handouts with instructions on finding the medication and available savings programs.
• Set a follow-up reminder at 2-3 days post-prescription to confirm the patient was able to start treatment.

Final Thoughts

Bismuth Subcitrate/Metronidazole/Tetracycline remains a first-line treatment for H. pylori, and the single-capsule formulation offers real adherence advantages. By proactively checking availability, allowing generic substitution, preparing backup options, and addressing cost barriers, you can help ensure your patients get treated without unnecessary delays.

Explore Medfinder for Providers for real-time stock checking, and see our companion article for providers on helping patients save money on this medication. For the latest shortage updates, check our provider shortage briefing.